The seventh annual TIL Therapies Summit convenes at a pivotal time for developers working to address treatment-resistant solid tumors, following the first approval of Tumor-Infiltrating Lymphocyte (TIL) therapy in the US and with regulatory decisions pending in other regions. This event remains the essential forum for the TIL community, dedicated to the mission of transforming the end-to-end development process and delivering best-in-class therapies to patients with high unmet needs.

The summit brings together a global collective of experts, including biopharma leaders, academic researchers, clinicians, and patients. Attendees will share cutting-edge research focused on major challenges and innovations within the field. Key topics include advancing engineered TILs, simplifying the manufacturing processes for easier scalability, and incorporating the lived experiences of patients treated with TIL therapies.